Genfit Management

Management criteria checks 3/4

Genfit's CEO is M. Prigent, appointed in Sep 2019, has a tenure of 4.67 years. total yearly compensation is €664.22K, comprised of 59.3% salary and 40.7% bonuses, including company stock and options. directly owns 0.062% of the company’s shares, worth €98.27K. The average tenure of the management team and the board of directors is 2.3 years and 6.9 years respectively.

Key information

M. Prigent

Chief executive officer

€664.2k

Total compensation

CEO salary percentage	59.3%
CEO tenure	4.7yrs
CEO ownership	0.06%
Management average tenure	2.3yrs
Board average tenure	6.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has M. Prigent's remuneration changed compared to Genfit's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	€664k	€394k	-€29m
Sep 30 2023	n/a	n/a	-€32m
Jun 30 2023	n/a	n/a	-€34m
Mar 31 2023	n/a	n/a	-€29m
Dec 31 2022	€632k	€375k	-€24m
Sep 30 2022	n/a	n/a	€12m
Jun 30 2022	n/a	n/a	€48m
Mar 31 2022	n/a	n/a	€58m
Dec 31 2021	€562k	€325k	€67m
Sep 30 2021	n/a	n/a	€14m
Jun 30 2021	n/a	n/a	-€39m
Mar 31 2021	n/a	n/a	-€70m
Dec 31 2020	€455k	€325k	-€101m
Sep 30 2020	n/a	n/a	-€84m
Jun 30 2020	n/a	n/a	-€67m
Mar 31 2020	n/a	n/a	-€66m
Dec 31 2019	€325k	€95k	-€65m

Compensation vs Market: M.'s total compensation ($USD708.66K) is about average for companies of similar size in the German market ($USD689.54K).

Compensation vs Earnings: M.'s compensation has increased whilst the company is unprofitable.

CEO

M. Prigent (54 yo)

4.7yrs

Tenure

€664,224

Compensation

Mr. M. Pascal Prigent has been Chief Executive Officer of Genfit SA since September 16, 2019. He served as Executive Vice President of Marketing & Commercial Development at Genfit SA since May 31, 2018 unt...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jean-Francois Mouney	Co-Founder & Chairman of the Board	6.9yrs	€359.01k	0.094% € 149.1k
M. Prigent	Chief Executive Officer	4.7yrs	€664.22k	0.062% € 98.3k
Bart Staels	Co-Founder & Chairman of the Scientific Advisory Board	no data	no data	no data
Thomas Baetz	Chief Financial Officer	3.1yrs	no data	no data
Pascal Caisey	Chief Operating Officer	2.2yrs	no data	0.0095% € 15.1k
Meriam Kabbaj	Chief Technology Officer	1.4yrs	no data	no data
Dean Hum	Chief Scientific Officer	2.3yrs	€795.03k	0.021% € 32.9k
Jean-Christophe Marcoux	Chief Corporate Affairs Officer	1.2yrs	no data	0.0094% € 14.9k
Laurent Lannoo	Corporate Secretary & Director of Legal Affairs	16.3yrs	no data	0.023% € 36.0k
Stefanie Magner	Chief Compliance Officer & Executive VP of International Legal Affairs	3.2yrs	no data	0.0056% € 8.8k
Emilie Desodt	Executive Vice President of Human Resources	2.2yrs	no data	0.0035% € 5.6k
Sakina Sayah-Jeanne	Executive VP of Research & Translational Science	1.1yrs	no data	no data

2.3yrs

Average Tenure

51.5yo

Average Age

Experienced Management: XUP's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jean-Francois Mouney	Co-Founder & Chairman of the Board	6.9yrs	€359.01k	0.094% € 149.1k
Bart Staels	Co-Founder & Chairman of the Scientific Advisory Board	no data	no data	no data
Philippe Moons	Board Observer	3.3yrs	€13.75k	0.0021% € 3.3k
Florence Séjourné	Director	6.9yrs	no data	no data
Xavier des Buttes	Independent Vice-Chairman of the Board	6.9yrs	€80.66k	0.0037% € 5.9k
Scott L. Friedman	Member of Scientific Advisory Board	no data	no data	no data
Arun Sanyal	Member of Scientific Advisory Board	no data	no data	no data
Michael Trauner	Member of Scientific Advisory Board	no data	no data	no data
Catherine Larue	Independent Director	6.9yrs	€43.60k	no data
Vlad Raziu	Member of Scientific Advisory Board	no data	no data	no data
Anne-Helene Monsellato	Independent Director	6.9yrs	€39.24k	no data
Katherine Kalin	Independent Director	3.8yrs	€39.24k	0.010% € 16.0k

6.9yrs

Average Tenure

63yo

Average Age

Experienced Board: XUP's board of directors are considered experienced (6.9 years average tenure).

Genfit Management

Management criteria checks 3/4

Key information

Recent management updates

Insufficient new directors

Genfit S.A., Annual General Meeting, May 22, 2024

GENFIT Announces Board Changes

Genfit SA, Annual General Meeting, May 28, 2021

Pascal Caisey and Philippe Motté Join the Executive Committee of GENFIT

Recent updates

Full year 2023 earnings released: €0.58 loss per share (vs €0.48 loss in FY 2022)

Insufficient new directors

Genfit S.A., Annual General Meeting, May 22, 2024

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

GENFIT Announces Publication in Nature Medicine Confirming the Performance of Its Nash Diagnostic Technology

First half 2023 earnings released: €0.42 loss per share (vs €0.21 loss in 1H 2022)

New minor risk - Profitability

Genfit S.A. Announces the Publication of New Data on the Clinical Performance of NIS2+(TM) in Older Patients in Hepatology Communications

New minor risk - Profitability

New minor risk - Share price stability

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week as part of its ACLF Program

Full year 2022 earnings released: €0.48 loss per share (vs €1.50 profit in FY 2021)

Genfit S.A. to Report First Half, 2023 Results on Sep 20, 2023

Genfit S.A. (ENXTPA:GNFT) acquired Versantis AG for approximately CHF 110 million.

First half 2022 earnings released: €0.21 loss per share (vs €0.21 profit in 1H 2021)

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG for approximately CHF 110 million.

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG from a group of investors for approximately CHF 110 million.

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: €1.51 (vs €2.61 loss in FY 2020)

Forecast to breakeven in 2022

First half 2021 earnings released: EPS €0.21 (vs €1.36 loss in 1H 2020)

GENFIT Presents New NIS4® Data in NASH at the International Liver Congress™ and the 81St Scientific Sessions of the American Diabetes Association

GENFIT Announces the Launch of NASHnext®, a Novel, Noninvasive Diagnostic Test for Nonalcoholic Steatohepatitis

Full year 2020 earnings released: €2.60 loss per share (vs €1.76 loss in FY 2019)

Full year 2020 earnings released

GENFIT Announces Board Changes

Genfit SA to Report Fiscal Year 2020 Results on Apr 01, 2021

New 90-day high: €5.19

Genfit SA, Annual General Meeting, May 28, 2021

GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology

Pascal Caisey and Philippe Motté Join the Executive Committee of GENFIT

New 90-day high: €4.75

Robbins LLP Announces That Purchaser of Genfit SA American Depository Shares Filed Class Action Complaint Against the Company and Its Officers and Directors for Alleged Violations of the Securities Act of 1933

Genfit Presents New Data at AASLD The Liver Meeting Digital Experience™

Genfit and Labcorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease

First half earnings released

GENFIT Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluating Elafibranor in PBC

Genfit SA to Report First Half, 2020 Results on Sep 30, 2020

New 90-day low: €3.59

New 90-day low - €3.99

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age